Ronald Kalmeijer

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem et al. · Gastroenterology · 2014 · 256 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson et al. · Journal of Medicinal Chemistry · 2014 · 215 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Paul Y. Kwo, Norman Gitlin, Ronald Nahass et al. · Hepatology · 2016 · 189 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16